CYTOMX THERAPEUTICS INC (CTMX) Forecast, Price Target & Analyst Ratings

NASDAQ:CTMX • US23284F1057

Current stock price

4.56 USD
0 (0%)
At close:
4.52 USD
-0.04 (-0.88%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYTOMX THERAPEUTICS INC (CTMX).

Forecast Snapshot

Consensus Price Target

Price Target
$13.90
+ 204.77% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.13
Revenue Estimate
4.765M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$13.90
Upside
+ 204.77%
From current price of $4.56 to mean target of $13.90, Based on 15 analyst forecasts
Low
$10.10
Median
$13.77
High
$17.85

Price Target Revisions

1 Month
60.29%
3 Months
92.68%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for CTMX. The average price target is 13.9 USD. This implies a price increase of 204.77% is expected in the next year compared to the current price of 4.56.
The average price target has been revised upward by 92.68% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CTMX Current Analyst RatingCTMX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

CTMX Historical Analyst RatingsCTMX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.33%
CTMX was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CTMX.
In the previous month the buy percentage consensus was at a similar level.
CTMX was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-23Piper SandlerMaintains Overweight -> Overweight
2026-03-19BarclaysMaintains Overweight -> Overweight
2026-03-18GuggenheimMaintains Buy -> Buy
2026-03-18JefferiesMaintains Buy -> Buy
2026-03-17WedbushMaintains Outperform -> Outperform
2026-03-16JP MorganUpgrade Neutral -> Overweight
2026-03-16HC Wainwright & Co.Maintains Buy -> Buy
2026-03-09GuggenheimReiterate Buy -> Buy
2026-02-04Cantor FitzgeraldMaintains Overweight -> Overweight
2026-02-04BarclaysMaintains Overweight -> Overweight
2026-01-20GuggenheimInitiate Buy
2026-01-20BarclaysMaintains Overweight -> Overweight
2026-01-20Piper SandlerMaintains Overweight -> Overweight
2025-11-11HC Wainwright & Co.Maintains Buy -> Buy
2025-10-21BarclaysMaintains Overweight -> Overweight
2025-09-22Cantor FitzgeraldInitiate Overweight
2025-07-31OppenheimerInitiate Outperform
2025-05-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-05-15Piper SandlerMaintains Overweight -> Overweight
2025-05-15HC Wainwright & Co.Upgrade Neutral -> Buy
2025-04-14Piper SandlerMaintains Overweight -> Overweight
2025-03-07HC Wainwright & Co.Reiterate Neutral -> Neutral
2025-01-07HC Wainwright & Co.Reiterate Neutral -> Neutral
2024-11-11HC Wainwright & Co.Reiterate Neutral
2024-09-13HC Wainwright & Co.Reiterate Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.13
Revenue Estimate
4.765M
Revenue Q2Q
-90.64%
EPS Q2Q
-147.08%
Number of Analysts
10

Next Earnings Revisions

Revenue (1 Month)
-25.65%
Revenue (3 Months)
-29.91%
EPS (1 Month)
-26.53%
EPS (3 Months)
-25.26%

Next Earnings Summary

CTMX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.13 USD and the consensus revenue estimate is 4.76M USD.
The next earnings revenue estimate has been revised downward by 29.91% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CTMX revenue by date.CTMX revenue by date.
101.214M
90.25%		138.103M
36.45%		76.201M
-44.82%		26.996M
-64.57%		34.345M
27.22%		58.823M
71.27%		140.81M
139.38%		233.19M
65.61%		349.99M
50.09%		362.61M
3.61%		465.12M
28.27%
EBITDA
YoY % growth
CTMX ebitda by date.CTMX ebitda by date.
-4.309M
95.28%		26.763M
721.10%		-20.988M
-178.42%		-73.95M
-252.34%		-82.62M
-11.72%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CTMX ebit by date.CTMX ebit by date.
-6.484M
93.07%		24.995M
485.49%		-22.364M
-189.47%		-89.975M
-302.32%		-100.594M
-11.80%		-92.064M
8.48%		-5.474M
94.05%		65.71M
1,300.40%		153.65M
133.83%		150.45M
-2.08%		231.54M
53.90%
Operating Margin
CTMX operating margin by date.CTMX operating margin by date.
-6.41%18.10%-29.35%-333.29%-292.89%-156.51%-3.89%28.18%43.90%41.49%49.78%
EPS
YoY % growth
CTMX eps by date.CTMX eps by date.
-0.02
98.68%		0.39
2,050.00%		-0.04
-110.51%		-0.39
-854.50%		-0.38
2.07%		-0.30
22.81%		0.07
124.14%		0.06
-21.43%		0.94
1,572.73%		1.31
39.13%		1.46
11.72%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.13
-147.08%		-0.09
-8,889.26%		-0.13
-46.48%		-0.14
36.71%		-0.12
3.71%		-0.14
-58.86%		-0.15
-16.05%		-0.16
-17.22%
Revenue
Q2Q % growth		4.765M
-90.64%		10.244M
-45.10%		3.381M
-43.30%		3.381M
409.95%		N/AN/AN/AN/A
EBITDA
Q2Q % growth		-29.58M
-228.58%		-31.62M
-5,607.58%		-35.7M
-139.57%		-41.82M
-57.48%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-23.405M
-203.47%		-17.406M
-1,253.50%		-26.794M
-69.93%		-28.697M
-2.74%		-29.415M
-25.68%		-32.985M
-89.50%		-35.025M
-30.72%		-38.085M
-32.71%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-93.23%
EPS Next 5 Year
27.49%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-11.60%
Revenue Next 5 Year
22.32%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CYTOMX THERAPEUTICS INC / CTMX Forecast FAQ

Can you provide the average price target for CYTOMX THERAPEUTICS INC stock?

15 analysts have analysed CTMX and the average price target is 13.9 USD. This implies a price increase of 204.77% is expected in the next year compared to the current price of 4.56.

What is the next earnings date for CTMX stock?

CYTOMX THERAPEUTICS INC (CTMX) will report earnings on 2026-05-11.

Can you provide the consensus estimates for CYTOMX THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of CYTOMX THERAPEUTICS INC (CTMX) is -0.13 USD and the consensus revenue estimate is 4.76M USD.

What is the consensus rating for CYTOMX THERAPEUTICS INC (CTMX) stock?

The consensus rating for CYTOMX THERAPEUTICS INC (CTMX) is 85.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.